Shots::stohShots:

• The P-II CITYSCAPE study involves assessing of tiragolumab+ Tecentriq (atezolizumab) vs Tecentriq + PBO to in 135 patients with 1L PD-L1-positive NSCLC. The full results of the study will be presented at ASCO20 Virtual Scientific Program
• The P-II study results: met its co-1EPs in IIT population- ORR (31.3% vs16.2%)- mPFS (5.4 vs 3.6mos.)- @exploratory analysis in people with high levels of PD-L1 (TPS ≥50%) ORR (55.2% vs 17.2%) with 67% reduction in the risk of disease worsening or death- @6mos. follow up- ORR (37.3% vs 20.6%) and mPFS (5.6 vs 3.9) in IIT population. Results in the PD-L1-high population were consistent with the first analysis and the median PFS was still not reached
• Tiragolumab is a mAb targeting TIGIT- acts by blocking its interaction with PVR- or CD155 that can suppress the body’s immune response

Click here to­ read full press release/ article 

Ref: Roche | Image: Roche